Last reviewed 2026-05-22 · How we verify

Barbidal (ALLOBARBITAL)

Phase 2 active Small molecule ✓ Verified May 2026

Barbidal (generic name: ALLOBARBITAL) is a allobarbital drug. It is currently in Phase 2 development.

Allobarbital works by enhancing the activity of neurotransmitters in the brain, leading to sedative and anticonvulsant effects.

Barbitald is a small molecule with synonyms including Allobarbitone, Allobarbital, and Diallylbarbituric acid.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ALLOBARBITAL
Drug class	allobarbital
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a busy city with many different streets and intersections. Neurotransmitters are like traffic signals that help different parts of the brain communicate with each other. Allobarbital helps these traffic signals work more efficiently, which can calm down overactive brain activity and reduce seizures.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Barbidal CI brief — competitive landscape report
Barbidal updates RSS · CI watch RSS

Frequently asked questions about Barbidal

What is Barbidal?

Barbidal (ALLOBARBITAL) is a allobarbital drug.

How does Barbidal work?

Allobarbital works by enhancing the activity of neurotransmitters in the brain, leading to sedative and anticonvulsant effects.

What is the generic name of Barbidal?

ALLOBARBITAL is the generic (nonproprietary) name of Barbidal.

What drug class is Barbidal in?

Barbidal belongs to the allobarbital class. See all allobarbital drugs at /class/allobarbital.

What development phase is Barbidal in?

Barbidal is in Phase 2.

Drug class: All allobarbital drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing